Publications
July 2025
Modeling highlights the challenge of maintaining HCV micro-elimination among people who inject drugs
Tatara E, et al.
2024
September 2024
Commentary on: Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Dahari, H., Cotler, SJ.
2023
July 2023
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
June 2023
Hepatitis delta virus RNA decline post inoculation in human NTCP transgenic mice is biphasic
April 2023
Rapid monophasic hepatitis B surface antigen decline during nucleic-acid polymers-based therapy predicts functional cure
January 2023
Modeling-Based Response-Guided Hepatitis C Treatment during Pregnancy and Postpartum
2022
October 2022
Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients
_PNG.webp)
June 2022
Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics
March 2022
Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago
January 2022
Mathematical modeling suggests that entry-inhibitor Bulevirtide may interfere with hepatitis D virus clearance from circulation
January 2022
Machine learning for mathematical models of HCV kinetics during antiviral therapy
January 2022
A meta-analysis of 20 years of data on people who inject drugs in metropolitan Chicago to inform computational modeling
2021
_PNG.webp)
2020
.webp)
2019
2018
_edited.jpg)
February
High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Networks Members
Boodram B, et al.
2017
December
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
Canini L et al.
October
A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics
Reinharz V, et al.
August
Modeling HCV cure after an ultra-short duration of therapy with direct acting agents
Goyal A, et al.
June
Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection
Canini L, et al.
May
End of treatment RNA-positive/sustained viral response in an individual with acute HCV infection treated with direct-acting antivirals
Shtyer E, et al.
January
Prevalence of End of Treatment RNA-Positivity/Sustained Viral Response in HCV Patients Treated with Sofosbuvir Combination Therapies
Malespin M, et al.
2016
June
HCV Kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
Dahari H, et al.
July
Hepatitis C virus cure after direct acting antiviral-related drug-induced liver injury: Case report
Hasin Y, et al.
September
HCV dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy
DebRoy S, et al.
.webp)
September
Resurrection of response-guided therapy for sofosbuvir combination therapies
Dahari H, et al.
2015
October
Oral Prenylation Inhibition with Lonafarnib in Chronic Hepatitis D Infection: a randomized, double-blinded, placebo controlled phase 2a trial
Koh C, et al.
September
Agent-based model forecasts aging of the population of people who inject drugs in metropolitan Chicago and changing prevalence of hepatitis C infections
Gutfraind A, et al.
August
Mathematical modeling of hepatitis C prevalence reduction with antiviral treatment scale-up in persons who inject drugs in metropolitan Chicago
Echevarria D, et al.
July
Quantification of HCV cell-to-cell spread using a stochastic modeling approach
Graw F, et al.
February
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics
Dahari H, et al.
January
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
Canini L, et al.
2014
January
Treatment of hepatitis C with an interferon-based lead-in phase: A perspective from mathematical modeling
​
​
Rong L, et al.
February
Effect of Ribavirin on Viral Kinetics and Liver Gene Expression in Chronic Hepatitis C
​​
​
​
Rotman Y, et al.
June
Individualized treatment for patients with low HCV load (genotype 1): A viral kinetic approach.
​
​
Dahari H, et al.
December
Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling
​
​
Guedj J, et al.
2013
March
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a new estimate of the hepatitis C virus half-life
Guedj J, Dahari H. et al.
March
Multiscale modeling approach predicts that the protease inhibitor danoprevir blocks several distinct stages of the HCV replication in vivo.
Rong L, et al.
April
Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection
Zhang J, et al.
April
Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling
Dahari H. et al.
July
The HCV NS5A inhibitor daclatasvir has dual mode of action and reveals a shorter HCV half-life estimate.
Guedj J, et al.
2011
2010
May
Pharmacodynamics of PEG-IFN alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes.
Dahari H, et al.
August
The rate of hepatitis C virus infection initiation in vitro is directly related to particle density
Sabahi A, et al.
_edited_edited.png)
September
Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells.
Neumann AU, et al.
2009
January
Modeling complex decay profiles of hepatitis B virus during antiviral therapy.
Dahari H, et al.
January
Analysis of hepatitis C virus infection models with hepatocyte homeostasis.
Reluga T​, et al.
January
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.
Dahari H, et al.
March
Modeling HCV kinetics: The relationship between the infected cell loss rate and the final slope of viral decay.
Dahari H, et al.
August
Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection.
Burg D, et al.
2008
2007
January
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated Interferon and ribavirin.
Dahari H, et al
June
Hepatitis C virus RNA kinetics: Drug efficacy and the rate of HCV-infected cells loss.
Dahari H, Perelson AS, et al.
October
Mathematical modeling of subgenomic hepatitis C viral replication in Huh-7 cells.
Dahari H, et al
December
Hepatitis C virus kinetics in chimeric mice during antiviral therapy.
Dahari H, Perelson AS, et al.
2006
_edited.png)
_edited_edited.png)
2002
July
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.
Bouvier-Alias M, et al.
2000
July
Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.
Neumann AU, et al.
1998
October
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
Neumann AU, et al.